Comment on “APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression”

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Llovet JM,Sia D.Molecular therapies and precision medicine for hepatocellular carcinoma..Nat Rev Clin Oncol2018;15:599-616

[3] Prieto J,Sangro B.Immunological landscape and immunotherapy of hepatocellular carcinoma..Nat Rev Gastroenterol Hepatol2015;12:681-700

[4] Llovet JM,Pikarsky E,Schwartz M.Hepatocellular carcinoma..Nat Rev Dis Primers2016;2:16018

[5] Wan S,Kryczek I,Welling TH.Myeloid cells in hepatocellular carcinoma..Hepatology2015;62:1304-12 PMCID:PMC4589430

[6] Lu LC,Hsu CH.Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives..J Hepatocell Carcinoma2019;6:71-84 PMCID:PMC6511249

[7] Degroote H,Geerts A,Devisscher L.Preclinical and Clinical Therapeutic Strategies Affecting Tumor-Associated Macrophages in Hepatocellular Carcinoma..J Immunol Res2018;2018:7819520 PMCID:PMC6206557

[8] Wang D,Li J,Zhao S.APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression..Gut2019;

[9] Cao R.SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex..Mol Cell2004;15:57-67

[10] Nagarsheth N,Zou W.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy..Nat Rev Immunol2017;17:559-72 PMCID:PMC5731833

[11] Nivolumab Approved for Liver Cancer..Cancer Discov2017;7:OF3

[12] Chen S,Wen W.Targeted therapy for hepatocellular carcinoma: Challenges and opportunities..Cancer Lett2019;460:1-9

[13] Toh TB,Chow EK.Epigenetics of hepatocellular carcinoma..Clin Transl Med2019;8:13 PMCID:PMC6500786